Corcept's Relacorilant Receives Positive CHMP Opinion in EU, Marking Key Regulatory Milestone

What happened

On September 18, 2026, Corcept announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended EU marketing authorization for Lifyorli (relacorilant). This positive opinion follows the company's NDA submission in the US and aligns with its strategy to expand relacorilant's global footprint beyond the core Cushing's franchise. While the CHMP opinion is a critical de-risking event for the EU market, it remains subject to final European Commission approval, and the US regulatory status is not addressed in this announcement. The recommendation marks a milestone in Corcept's efforts to diversify away from Korlym, whose revenue faces authorized generic competition and payer pressures. Investors will now watch for the final EC decision and any updates on the US FDA decision for relacorilant, which was expected by late 2025 but has not been disclosed in this article.

Implication

The CHMP recommendation meaningfully de-risks relacorilant's path to market in the EU, potentially unlocking a new revenue stream outside the US. However, the European market is often characterized by longer reimbursement timelines and pricing negotiations, which may delay significant revenue contribution. The US remains the largest opportunity, and without explicit confirmation of FDA approval, the stock's valuation may not fully reflect the upside. Positive EU opinion may increase confidence that the drug's safety and efficacy profile is acceptable to regulators, which could indirectly support the US case. Investors should monitor final EC approval and any US regulatory updates, as well as Korlym's persistence against generics, to reassess the thesis.

Thesis delta

The previous HOLD/NEUTRAL stance was predicated on binary regulatory risk for relacorilant in Cushing's. The CHMP positive opinion reduces the risk of non-approval in the EU, but the US FDA decision remains unknown. This shifts the balance slightly more positive, but a full upgrade to BUY still requires confirmation of US approval and sustained Korlym performance.